Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(9):739; doi:10.1093/jnci/91.9.739
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 9, 739, May 5, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Arsenic Trioxide and Lymphocytic Cancers

Arsenic trioxide can induce clinical remission in patients with acute promyelocytic leukemia. This anticancer effect is brought about by the induction of cellular differentiation and apoptosis (programmed cell death). Zhu et al. (p. 772) have investigated whether clinically achievable concentrations of arsenic trioxide could also cause growth inhibition, differentiation, and apoptosis in malignant lymphocytes. They found that therapeutic concentrations (1-2 µM) of arsenic trioxide could substantially inhibit cell growth and induce apoptosis in most of the malignant lymphocytic cell types studied. According to the authors, these results suggest that arsenic trioxide may prove . . . [Full Text of this Article]

Exposure to Dioxin and Cancer

Gastric Cardia Cancer Misclassification

A Molecular Key to Uterine Leiomyosarcomas?

Gene Therapy for Lung Cancer

Detecting Nasopharyngeal Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?